Skip to main content

Advertisement

SpringerLink
Log in

Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

  • Topic paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

One third of patients with metastatic renal cell carcinoma (RCC) suffer from bone metastases. Skeletal involvement in RCC is associated with the occurrence of skeletal-related events, and may negatively impact on the outcome of patients treated with systemic therapies. In patients with RCC and bone metastases, therapies that inhibit osteoclasts, as bisphosphonates and denosumab, are used as adjunct to systemic targeted therapies to prevent skeletal-related events. Data suggest that they may also improve the outcome of systemic targeted therapies. Herein we review the preclinical and clinical data on their use, as well as remaining open questions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284–291

    Article  PubMed  Google Scholar 

  3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23:202–212

    Article  CAS  PubMed  Google Scholar 

  4. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875

    Article  CAS  PubMed  Google Scholar 

  5. Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843–852

    Article  PubMed  Google Scholar 

  6. Zagoria RJ, Bechtold RE (1997) The role of imaging in staging renal adenocarcinoma. Semin Ultrasound CT MR 18:91–99

    Article  CAS  PubMed  Google Scholar 

  7. Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160–166

    Article  PubMed  Google Scholar 

  8. Zekri J, Ahmed N, Coleman RE, Hancock BW (2011) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379–382

    Google Scholar 

  9. Khattak MA, Martin HL (2012) Management of bone metastases from advanced renal cell carcinoma. Eur J Cancer Jun 6. [Epub ahead of print]

  10. Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22:794–800

    Article  CAS  PubMed  Google Scholar 

  11. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22:295–300

    Article  CAS  PubMed  Google Scholar 

  12. Yuasa T, Urakami S, Yamamoto S et al (2011) Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis 28:405–411

    Article  CAS  PubMed  Google Scholar 

  13. Tan TH, Pranavan G, Haxhimolla HZ, Yip D (2010) New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia Pacific J Clin Oncol 6:5–18

    Article  Google Scholar 

  14. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. NEJM 356:115–124

    Article  CAS  PubMed  Google Scholar 

  15. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    Article  CAS  PubMed  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  17. Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T (2012) Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 130:677–684

    Article  CAS  PubMed  Google Scholar 

  18. Karaca H, Lale A, Dikilitas M, Ozkan M, Er O (2010) Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol 27:1023–1026

    Article  PubMed  Google Scholar 

  19. Żolnierek J, Nurzyński P, Langiewicz P et al (2009) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371–378

    Article  PubMed  Google Scholar 

  20. Saad F, Eastham JA (2010) Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol 37(Suppl 1):S38–S44. Review

    Google Scholar 

  21. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157

    Article  CAS  PubMed  Google Scholar 

  22. Rosen LS, Gordon D, Tchekmedyain NS et al (2004) Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumours. Cancer 100:2613–2621

    Article  CAS  PubMed  Google Scholar 

  23. Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962–969

    Article  CAS  PubMed  Google Scholar 

  24. Ullen A, Schwarz S, Lennartsson L et al (2009) Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 43:98–103

    Article  CAS  PubMed  Google Scholar 

  25. Pandha H, Birchall L, Meyer B et al (2006) Antitumor effects of amino bisphosphonates on renal cell carcinoma cell lines. J Urol 176:2255–2261

    Article  CAS  PubMed  Google Scholar 

  26. Soltau J, Zirrgiebel U, Esser N et al (2008) Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 28:933–941

    CAS  PubMed  Google Scholar 

  27. Kijima T, Fujii Y, Suyama T, Okubo Y, Yonese J, Fukui I (2008) Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. Int J Urol 15:546–547

    Article  PubMed  Google Scholar 

  28. Beuselinck BL, Medioni J, Wolter P et al (2011) Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib. J Clin Oncol 29(suppl 7), abstr 388

    Google Scholar 

  29. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA (2012) Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer 48:1031–1037

    Article  CAS  PubMed  Google Scholar 

  30. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I (2012) Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol Sep 11. [Epub ahead of print]

  31. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664

    Article  CAS  PubMed  Google Scholar 

  32. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218:530–539

    Article  CAS  PubMed  Google Scholar 

  33. Henry DH, Costa L, Goldwasser FJ et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132

    Article  CAS  PubMed  Google Scholar 

  34. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    Article  CAS  PubMed  Google Scholar 

  35. Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17

    Article  CAS  PubMed  Google Scholar 

  36. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347

    Article  CAS  PubMed  Google Scholar 

  37. Christodoulou C, Pervena A, Klouvas G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211

    Article  CAS  PubMed  Google Scholar 

  38. Ayllon J, Vacher-Launay V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20:600–601

    Article  CAS  PubMed  Google Scholar 

  39. Brunello A, Saia G, Bedogni A, Scaglioni D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173–175

    Article  CAS  PubMed  Google Scholar 

  40. Hoefert S, Eufinger H (2010) Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:463–469

    Article  PubMed  Google Scholar 

  41. Aragon-Ching JB, Dahut WL (2008) Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist 13:1314

    Article  PubMed  Google Scholar 

  42. Chennuru S, Koduri J, Baumann MA (2008) Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J 38:635–637

    Article  CAS  PubMed  Google Scholar 

  43. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Tchernichovsky 59, 44281, Kfar-Saba, Israel

    Daniel Keizman, Maya Ish-Shalom, Natalie Maimon & Maya Gottfried

Authors
  1. Daniel Keizman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maya Ish-Shalom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalie Maimon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maya Gottfried
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Keizman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keizman, D., Ish-Shalom, M., Maimon, N. et al. Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?. World J Urol 32, 39–45 (2014). https://doi.org/10.1007/s00345-013-1059-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-013-1059-6

Keywords

Search

Navigation